Bone metastases of non–small cell lung cancer (NSCLC) may present an osteolytic or osteoblastic pattern, and their occurrence during treatment qualifies as progressive disease. However, “osteoblastic responses” (the appearance of either new osteoblastic lesions or a sclerotic component within preexisting lytic lesions) have been described, particularly in epidermal growth factor receptor gene (EGFR)-addicted NSCLC READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2016.04.002
Authors: Francesco Gelsomino, Valentina Ambrosini, Barbara Melotti, Francesca Sperandi, Andrea Ardizzoni
